




 Purinergic signaling pathways regulate airways defense mechanisms, including mucociliary clear-
ance and infl ammatory responses. These pathways 
are activated by extracellular purines, which include 
adenosine triphosphate (ATP) and its metabolites 
adenosine diphosphate, adenosine monophosphate 
(AMP), and adenosine. Adenosine, in particular, has 
been linked to infl ammatory airways diseases, 1  includ-
ing twofold to fourfold elevations in blood 2,3 and 
BAL fl uid 4 of subjects with asthma. Similarly, ade-
nosine concentrations in exhaled breath condensate 
(EBC) are elevated in subjects with stable asthma, 5,6 
increased with asthma exacerbations, 7 and decreased 
with successful treatment. Findings from animal mod-
els, particularly the adenosine deaminase knockout 
mouse, 8,9 further support a link between airway infl am-
mation and lung adenosine. 
 These data suggest that purinergic signaling path-
ways may be active in infl ammatory lung diseases 
such as COPD and may be targets for therapeutic 
intervention. 10 Indeed, elevated airway adenosine 
concentrations in COPD have been inferred from 
studies of human airway adenosine receptors, 11 and 
several reviews have touted potential benefi ts of 
pharmacologic blockade of adenosine receptors. 10,12 
Although these benefi ts are a reasonable extrapola-
tion from the animal 8,13 and human studies, 4,5 a recent 
investigation suggested that airway adenosine con-
centrations (as measured in sputum) may actually be 
lower in COPD. 14 However, adenosine concentrations 
in respiratory samples such as sputum or BAL can 
be altered unpredictably by extracellular metabolism 
during processing or by mechanical and osmotic 
forces that trigger purine release during collection. 
 Background:  Adenosine and related purines have established roles in infl ammation, and elevated 
airway concentrations are predicted in patients with COPD. However, accurate airway surface 
purine measurements can be confounded by stimulation of purine release during collection of 
typical respiratory samples. 
 Methods:  Airway samples were collected noninvasively as exhaled breath condensate (EBC) from 
36 healthy nonsmokers (NS group), 28 healthy smokers (S group), and 89 subjects with COPD 
(29 with GOLD [Global Initiative for Chronic Obstructive Lung Disease] stage II, 29 with GOLD 
stage III, and 31 with GOLD stage IV) and analyzed with mass spectrometry for adenosine, 
adenosine monophosphate (AMP), and phenylalanine, plus urea as a dilution marker. Variable 
dilution of airway secretions in EBC was controlled using ratios to urea, and airway surface concen-
trations were calculated using EBC to serum urea-based dilution factors. 
 Results:  EBC adenosine to urea ratios were similar in NS (0.20   0.21) and S (0.22   0.20) groups 
but elevated in those with COPD (0.32   0.30,  P  , .01 vs NS). Adenosine to urea ratios were highest 
in the most severely affected cohort (GOLD IV, 0.35   0.34,  P  , .01 vs NS) and negatively corre-
lated with FEV 1 ( r  5  2 0.27,  P  , .01). Elevated AMP to urea ratios were also observed in the COPD 
group (0.58   0.97 COPD, 0.29   0.35 NS,  P  , .02), but phenylalanine to urea ratios were similar 
in all groups. Airway surface adenosine concentrations calculated in a subset of subjects were 
3.2   2.7  m M in those with COPD (n  5 28) relative to 1.7   1.5  m M in the NS group (n  5 16,  P  , .05). 
 Conclusions:  Airway purines are present on airway surfaces at physiologically signifi cant concen-
trations, are elevated in COPD, and correlate with markers of COPD severity. Purinergic sig-
naling pathways are potential therapeutic targets in COPD, and EBC purines are potential 
noninvasive biomarkers.   CHEST 2011; 140(4):954–960 
 Abbreviations: AMP  5 adenosine monophosphate; ANOVA  5 analysis of variance; EBC  5 exhaled breath condensate; 
ECLIPSE  5 Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points; GOLD  5 Global Initiative 
for Chronic Obstructive Lung Disease; NS  5 nonsmoker; S  5 smoker 
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Samples for ECLIPSE were collected in 2006 and were ana-
lyzed in mid-2009. Demographic characteristics of the sub-
jects in whom EBC biomarkers were successfully measured are
in  Table 1 . Pulmonary function tests were performed as previ-
ously described. 19 In RES19044, BUN was measured in serum 
obtained on the day of EBC collection. The samples from ECLIPSE 
represented a subset of that larger study chosen such that the 
subject demographics matched those of RES19044. 
 Mass Spectrometric Analysis 
 Sixty-one samples from RES19044 and 102 from ECLIPSE 
were analyzed using a previously published method 6,15 ( Fig 1A ) 
modifi ed to account for variable volumes. As previously 
described, 15 500  m L of EBC (total volume if  , 500  m L) plus a 
1:20 ratio of internal standard solution (50 nM [ 13 C,  15 N] ade-
nosine, 250 nM [ 15 N] AMP, and 50  m M [ 13 C] plus isotopically 
labeled amino acids [NSK-A; Cambridge Isotope Laboratories, 
Inc; Andover, Massachusetts]) were lyophilized, resuspended, 
and subjected to mass spectrometric analysis of urea, adenosine, 
and AMP. A second aliquot of up to 500  m L was processed as 
described here for replicate analysis if suffi cient volume was avail-
able. Detection of phenylalanine (166 → 120) and isotopically labeled 
internal standard (172 → 126) was added during the course of the 
study. Peak areas for biomarkers and internal standards were 
determined via an automated processing program (Xcalibur; 
ThermoFinnigan; San Jose, California) and concentrations calcu-
lated from standard curves run in parallel. The average of dupli-
cate measures was used when available. 
 Ten samples (three from RES19044, seven from ECLIPSE) 
were excluded from further analysis: three likely contaminants 
(adenosine and AMP levels  . 3 orders of magnitude above the 
mean); seven with urea concentrations below reliable quantifi ca-
tion threshold of 1  m M as determined in a previous study. 15 Sam-
ples with subthreshold urea measurements were excluded since 
we could not determine the extent of dilution of airway secretions 
within the condensate. Two samples with AMP concentrations 
below quantifi able limits were assigned a value of one-half of the 
lowest measured concentration. 
 Statistical Analysis 
 EBC and demographic data are reported as mean   SD. Log 
transformation of EBC biomarkers was used to yield normal dis-
tributions by D’Agostino-Pearson test. To adjust for differences 
between studies, a two-way analysis of variance (ANOVA) model 
was used including study and cohort as factors, using the standard 
F-test to assess cohort differences. For signifi cant results, pair-
wise differences were investigated with the Tukey-Kramer post-
test adjustment. Linear contrasts were used to assess linear trends 
across cohorts as well as to test various group differences. 
 Results 
 Adenosine and Other Biomarkers Measured in EBC 
 Airway concentrations of purines and other metab-
olites were successfully measured in EBC from 
153 subjects: 36 healthy nonsmokers (NS group), 
28 healthy smokers (S group), and 89 subjects with 
COPD (GOLD stage II, 29; GOLD stage III, 29; and 
GOLD stage IV, 31). Age and gender distribution was 
generally similar among cohorts, whereas FEV 1 was 
decreased signifi cantly in COPD ( Table 1 ). Use of 
inhaled corticosteroids was common in the COPD 
 To assess airway purine concentrations noninva-
sively in COPD, we applied a previously reported mass 
spectrometric method 6,15 to measure adenosine, AMP, 
and phenylalanine, plus urea as a dilution marker, in 
EBC collected from participants in two multicenter 
observational studies. Variable dilution of airway 
secretions within EBC was controlled by assessing 
biomarkers as ratios to urea or using serum to EBC 
urea-based dilution factors. 16 Data were analyzed 
relative to GOLD (Global Initiative for Chronic 
Obstructive Lung Disease) stage 17 and lung function 
(FEV 1 % predicted) to provide insights into the role 
of purinergic signaling in COPD disease progression. 
 Materials and Methods 
 Study Subjects 
 Subjects were participants in one of two observational studies: 
RES19044 (A Multi-center Cohort Study to Evaluate Radiological, 
Physiological and Biochemical Biomarkers in Patients with Chronic 
Obstructive Pulmonary Disease and Age and Gender Matched 
Controls) 18 or ECLIPSE (Evaluation of COPD Longitudinally 
to Identify Predictive Surrogate End-points) (clinicaltrials.gov; Iden-
tifi er: NCT00292552). 19 RES19044 was approved by Institutional 
Review Boards at St. Elizabeth’s Medical Center (00195) and the 
University of Pennsylvania (801096), and details for ECLIPSE are 
as previously published. 19 Subjects were diagnosed based on GOLD 
criteria (using postbronchodilator FEV 1 and FVC) and assigned to 
one of fi ve cohorts at screening: healthy nonsmokers (NS group), 
healthy current or former smokers (S group), or one of three 
COPD cohorts (GOLD stages II, III, or IV). Patients with known 
respiratory disorders other than COPD were excluded. 
 Study Design 
 In both studies, EBC was collected by having subjects exhale 
through an RTube (Respiratory Research, Inc; Charlottesville, 
Virginia) using tidal breathing for 10 min, with the chiller held 
at  2 70°C until immediately prior to collection. Smokers refrained 
from smoking   3 h prior to collection. Samples were stored 
at  2 80°C and shipped on dry ice to the University of North 
Carolina at Chapel Hill for analysis. Samples for RES19044 
were collected from 2005 to 2006 and were analyzed in late 2007. 
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posttest analyses demonstrating elevations in COPD 
(0.32   0.30) relative to NS groups (0.20   0.21,  P  , .01) 
with a trend toward statistical difference from the 
S group (0.22   0.20,  P  5 .09) ( Fig 2A ). In contrast, 
EBC phenylalanine to urea ratios were similar among 
the cohorts ( Fig 2B ). Analysis with COPD groups 
stratifi ed by GOLD stage revealed that EBC ade-
nosine to urea ratios differed among the cohorts 
( P  , .03 by ANOVA), with the highest ratios pres-
ent in GOLD stage IV (0.35   0.34,  P  , .02 vs NS) 
( Fig 2C ) and an increasing linear trend between 
EBC adenosine to urea ratios and cohort ( P  , .01). 
Smoking status was not independently predictive 
of EBC adenosine to urea ratio (not shown). Consis-
tent with these observations, a modest but statistically 
signifi cant negative correlation between EBC ade-
nosine to urea ratio and percent predicted FEV 1 was 
observed ( r  5  2 0.27,  P  , .01) ( Fig 2D ). 
 Extracellular adenosine and other purines can 
be derived from metabolism of extracellular ATP, 20 
cohorts ( Table 1 ), as was use of inhaled long-acting  b 
agonists (73% of all subjects with COPD) and inhaled 
anticholinergics (67%). EBC urea correlated signifi -
cantly with EBC adenosine and AMP ( r  5 0.39, 0.41, 
respectively, by Spearman,  P  , .001 for both), consis-
tent with urea as a dilution marker. Within-sample 
reproducibility (accuracy) was assessed through repli-
cate analyses of a subset with suffi cient volume (n  5 17, 
11 control subjects, six subjects with COPD), with 
data analyzed as ratios to urea. 6 Strong correlations 
were observed between replicate analyses ( r  5 0.96 
for adenosine to urea,  r  5 0.93 for AMP to urea), with 
good agreement by Bland-Altman analysis ( Fig 1B ). 
 EBC Adenosine Is Elevated in COPD and 
Correlates With Disease Severity 
 Comparing EBC adenosine to urea ratios in the 
NS, S, and COPD groups revealed that the ratios 
differed among the groups ( P  , .01 by ANOVA), with 
 Table 1— Subject Demographics 
Demographic 
Control Subjects Subjects With COPD
NS S II III IV
No. 36 28 29 29 31
Age, y 60.9   9.4 62.5   9.1 60.8   8.2 61   7.5 62   7.6
Gender, male (female) 18 (18) 19 (9) 14 (15) 18 (11) 16 (15)
FEV 1 , % predicted 108.9   12.6 107.9   12.9 61.9   10.5 a 39.8   8.5 a 24.1   4.1 a 
ICS, % 3 0.0 69 97 81
BUN b 16.4   6.5 18.8   12.4 16.1   4.1 16.8   5.6 17.4   8.6
II  5 GOLD stage II; III  5 GOLD stage III; IV  5 GOLD stage IV; GOLD  5 Global Initiative for Chronic Obstructive Lung Disease; ICS  5 inhaled 
corticosteroids; NS  5 healthy nonsmoker; S  5 healthy smoker.
 a P  , .01 vs all other cohorts.
 b BUN was assessed in a subset of subjects (16 NS, nine S, 10 GOLD II, seven GOLD III, 11 GOLD IV).
 Figure 1. A, Chromatogram demonstrating detection of urea, adenosine, AMP, and isotopically labeled 
internal standards within an exhaled breath condensate (EBC) from a subject with COPD. B, 
Bland-Altman plot of replicate analysis of 17 samples demonstrated that most replicates fell within 
the 95% limits of agreement (circles and dotted lines represent adenosine to urea ratio; triangles and 
dashed lines represent AMP to urea ratio). AMP  5 adenosine monophosphate. 
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GOLD stage IV). Serum urea did not vary signifi -
cantly among cohorts (see  Table 1 ). Airway surface 
adenosine concentrations differed among the groups 
and were elevated in COPD cohorts (3.2   2.7  m M 
COPD, 1.7   1.5  m M NS,  P  , .05) ( Fig 4A ) and nega-
tively correlated to FEV 1 % predicted ( r  5  2 0.39, 
 P  , .01) ( Fig 4C ). No statistically signifi cant differ-
ences in corrected AMP concentrations were observed 
within this subset. 
 Calculated dilution factors within this subset var-
ied widely among the samples and were modestly but 
not significantly higher in COPD (median, 5,200; 
interquartile range, [IQR], 3,000-9,000) relative 
to healthy control subjects (median, 4,300; IQR, 
2,000-7,500 in NS plus S groups,  P  5 .33). To explore 
dilution of airway secretions in EBC in all subjects, 
we examined EBC urea as a surrogate measure of 
dilution. Interestingly, we observed a modest trend 
toward decreased EBC urea in subjects with COPD 
( P  5 .08 by ANOVA), which became statistically sig-
nifi cant with both healthy control groups considered 
together (median, 45  m M; IQR, 25-83  m M urea healthy 
control subjects; median, 36  m M; IQR, 21-55  m M urea 
COPD;  P  , .05 by Mann-Whitney) ( Fig 4A ). 
 Discussion 
 This study demonstrated that purine concentrations 
on airway surfaces, as measured through anal ysis of 
and concentrations of ATP have paralleled its metabo-
lite AMP in previous studies. 21 Therefore, we hypoth-
esized that extracellular AMP concentrations would 
be elevated if ATP was the source of elevated purines 
(our assay was insuffi ciently sensitive to measure ATP 
directly). Consistent with this hypothesis, we observed 
increased EBC AMP to urea ratios in COPD relative 
to NS groups (0.58   0.97 COPD, 0.29   0.35 NS, 
 P  , .01). With the subjects with COPD stratifi ed 
by GOLD stage, EBC AMP to urea ratio differed 
among the cohorts and was signifi cantly elevated 
in GOLD stage IV (0.61   0.85 GOLD IV,  P  , .05 
vs NS) ( Fig 3A ), with an increasing linear trend 
between EBC AMP to urea ratio and cohort ( P  , .02). 
A weak but statistically signifi cant correlation between 
EBC AMP to urea ratio and FEV 1 % predicted was 
also observed ( r  5  2 0.17,  P  , .05) ( Fig 3C ). 
 Airway Surface Concentrations and Dilution in EBC 
 To assess airway surface concentrations of adenos-
ine, we used a previously described method to calcu-
late dilution factors based on ratios of urea EBC to urea 
in serum, 16,22 measured in a subset of subjects (16 NS 
group subjects, nine S group subjects, 10 with GOLD 
stage II, seven with GOLD stage III, and 11 with 
 Figure 2. EBC Ado was successfully measured in 36 healthy 
NS subjects (NS group), 28 healthy S subjects (S group), and 
89 subjects with COPD (29 GOLD II, 29 GOLD III, 31 GOLD IV) 
and reported as ratios of Ado (nM) to urea ( m M) to control 
for variable dilution of airway secretions. A, Ado to urea ratios 
differed among the cohorts and were elevated in subjects with 
COPD relative to NS. B, EBC Phe was measured from EBC from 
26 NS group subjects, 29 S group subjects, and 78 subjects with 
COPD; the Phe to urea ratio ( m M Phe to  m M urea) was similar 
among all cohorts. C, Analysis of Ado to urea ratio with subjects 
with COPD divided by GOLD stage; cohorts differed by analysis of 
variance (ANOVA) with Ado to urea ratio elevated in GOLD III 
and GOLD IV subjects relative to NS group subjects. D, A modest 
correlation ( r  5  2 0.27,  P  5 .002) was noted between EBC Ado to 
urea ratio and FEV 1 % predicted. * P  , .05 by ANOVA, † P  , .05 
vs NS by linear contrast with Tukey-Kramer adjustment. Ado  5 ade-
nosine; GOLD  5 Global Initiative for Chronic Obstructive Lung 
Disease; NS  5 nonsmoker; Phe  5 phenylalanine; S  5 smoker. See 
Figure 1 legend for expansion of other abbreviation. 
 Figure 3. EBC AMP was measured and assessed as ratios of 
AMP (nM) to urea ( m M). A, A trend toward group differences in 
NS, S, and COPD groups was observed ( P  5 .056 by ANOVA), 
and EBC AMP to urea ratio was elevated in subjects with COPD 
vs NS group subjects. B, Analysis of AMP to urea ratio with sub-
jects with COPD stratifi ed by GOLD stage. Cohorts did not 
differ signifi cantly by ANOVA ( P  5 .18), but a linear trend was 
noted between EBC AMP to urea ratio and cohort (r  5 0.132, 
 P  , .05). C, A weak but statistically signifi cant correlation between 
EBC AMP to urea ratio and percent predicted FEV 1 was noted 
( r  5  2 0.17,  P  , .05). † P  , .05 vs NS by linear contrast with Tukey-
Kramer adjustment. See Figure 1 and 2 legends for expansion of 
abbreviation. 
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 Our fi ndings suggest that purinergic signaling path-
ways play a role in the pathophysiology of COPD, 
differing from other reports suggesting that airway 
adenosine (measured in sputum) 14 and ATP (measured 
in EBC) 27 are not elevated in this disease. These con-
tradictory fi ndings may refl ect issues associated with 
different methods of collecting and analyzing airway 
secretions. For example, the sputum derived from 
the larger airways 28 may accumulate adenosine deam-
inase that lowers adenosine concentrations, whereas 
adenosine concentrations could remain elevated in 
the smaller airways from which airways secretions in 
EBC are generated. 29 Alternatively, sputum collec-
tion and processing may alter adenosine concentra-
tions, perhaps by osmotic or mechanically stimulated 
purine release or cellular activity/necrosis during sam-
ple preparation. 30 Such issues may also affect purine 
measures in BAL. 4,26 
 Although EBC collection does not introduce chemi-
cal gradients or expose airway surfaces to mechanical 
forces, 16,22 we cannot exclude the possibility that patient 
selection, storage time, or the particular EBC collec-
tion device used in this study infl uenced measured 
concentrations. Furthermore, the very low and highly 
variable fraction of airway secretions within the con-
densate posed considerable analytic challenges. We 
observed a nearly two orders of magnitude variation 
in dilution factors, consistent with several previous 
studies. 27,31,32 Controlling for dilution using ratios 
to urea or dilution factors provided a more accurate 
assessment of airway surface concentrations. Further-
more, decreased EBC urea in subjects with COPD 
suggests that EBC from these subjects may contain a 
smaller fraction of airway secretions than normal, 
although these decreases were modest and may have 
been diffi cult to detect in smaller studies. 22 Overall, 
these fi ndings reinforce the need to control for dilu-
tion when reporting nonvolatile biomarker concentra-
tions in EBC and complicate interpretation of studies 
in which EBC dilution was not measured, including 
the previous analysis of EBC ATP. 27 Our analyses 
suggest that a simple ratio to urea is suffi cient to con-
trol for dilution, and our mass spectrometry method 
offers the simplicity of measuring urea simultaneously 
with several biomarkers with the potential of adding 
novel biomarkers. 
 Dilution factor measurements allowed us to esti-
mate adenosine concentrations of   1 to 2  m M in 
healthy subjects. These values are much lower than 
the 60- m M concentrations reported in BAL fl uid, 4 
although not dissimilar to values measured in cul-
tured airway epithelia 33 and our own previous stud-
ies. 6 Given the likelihood that mechanical and osmotic 
forces may alter concentrations of purines measured 
in lavage or sputum, 30 estimates from EBC may more 
accurately refl ect the unperturbed airway, although 
EBC, are elevated in COPD and correlated with mark-
ers of disease severity. These results are consistent 
with previous human 4,5 and animal studies 9,13 that 
link adenosine and airway infl ammation and sug-
gest that this purine plays a pathophysiologic role 
in COPD. 10,23,24 Although indirect evidence of ele-
vated airway adenosine in COPD has previously been 
reported, 11 this study represents the fi rst direct mea-
surement of elevated airway adenosine in COPD. 
 Although the observed differences in airway purine 
concentrations were modest, they were similar in 
magnitude to those reported for EBC adenosine in 
asthma 5,7 and for other EBC biomarkers in COPD. 25 
Differences in adenosine may have been masked by 
treatment effects, since use of inhaled corticosteroids 
(common within our COPD cohorts) has been asso-
ciated with reduced EBC adenosine. 5 In addition, 
smoking has been shown to alter airway purines 4,26 
and may have made it more diffi cult to distinguish 
COPD from healthy smokers, although the strong 
relationship between COPD and smoking limited 
our ability to directly assess the impact of smoking 
in this study. Indeed, our fi ndings support a model 
in which infl ammatory responses to smoking result 
in increased airway purines (adenosine and AMP), 
which intensify as chronic infl ammation develops and 
worsens in COPD. This mechanism is consistent with 
a recently published study demonstrating increased 
ATP in BAL fl uid of smokers and subjects with 
COPD. 26 
 Figure 4. A, Concentrations of Ado in airway surface liquid were 
calculated using EBC to serum urea-based dilution factors. Air-
way surface Ado concentrations differed among the cohorts and 
were higher in subjects with COPD relative to NS group subjects. 
* P  , .05 by analysis of variance,  †  P  , .05 vs NS. B, Airway Ado 
concentrations correlated with FEV 1 % predicted ( r  5  2 0.39, 
 P  , .01). C, EBC urea concentrations (measured after lyophiliza-
tion) were assessed as a surrogate marker of dilution available in the 
entire cohort. Values were highly variable but modestly lower in 
subjects with COPD relative to healthy control subjects. * P  , .05 
by Mann-Whitney. See Figure 1 and 2 legends for expansion of 
abbreviations. 
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potentially limited by experimental and treatment 
effects noted previously. Nevertheless, our measured 
concentrations remain above the submicromolar EC 50 
values of the A 1 , A 2A , and A 3 adenosine receptors 
found on airway epithelial and infl ammatory cells. 34 
Although signaling via these receptors triggers 
complex responses, activation of the A 2A receptor 
(and possibly the A 1 receptor) generally suppresses 
infl ammatory responses. 1,10 Thus, our results suggest 
that airway adenosine may be antiinfl ammatory at 
the concentrations observed in the healthy airway. 
In contrast, higher adenosine concentrations in 
COPD may increase A 2B receptor activation, which 
has a higher EC 50 34 and has been associated with more 
proinfl ammatory responses. 1 Although these hypoth-
eses are appealing, the relationships refl ect complex 
relationships between various receptor subtypes and 
infl ammatory cascades. Furthermore, localized eleva-
tions of adenosine (eg, from metabolism of AMP at 
cell surfaces 35 ) could trigger signaling events without 
signifi cant alteration of adenosine concentrations in air-
way secretions as measured by EBC or other methods. 
 In summary, our data indicate that airway purines 
are elevated in subjects with COPD and can be 
assessed simply and noninvasively by mass spectro-
metric analysis of EBC. These fi ndings suggest that 
purinergic signaling pathways may be an appropri-
ate target for therapeutic intervention. With further 
study to better defi ne variability and reproducibility, 
evaluation of EBC purines (appropriately corrected 
for dilution) could serve as biomarkers of disease 
severity in COPD. 
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